EXHIBIT 3

May 28,2005

Clerk of the United States Barknupcy Courts
for the District of Delawater
824 Market Street
Wilnington Delawater 19801

Ro: LIR. Grace/CO., ot al., Cose# OHO139 (JFK)

Honorable Cletk

FILED
PH 1: 54
PHIS JUNE 10 PH 1: 54
PHIS PANATOR OF DELAMARE

At this time writing I am informing the courts of my inability to access the law library to be able to make copies of documents to use to source books, directorys, type writers to complete cortain requirements in respondto civil as well as criminial matters that I face.

The tensor is the restrictive polices that the CD.C. tas implemented last October 2004 to the Prisoner-Patrient (Iam a Patrient of the D.M. Hat the E.O.P.) from utilizing the facilities of law library, the tensors are orteated, that you.

Sincetly

Raphod & Palazzo

Dated May 28,2005

In The United States Barkrupcy Court
For the District of Delaware

In to:

Gaptet 11

W.R. Gross \$Co., ot al., & Cose No. OH B9 (JFK)

Debetor D(Jointly Administrated)

Objection to the Debtors' Eleventh Omnibus Objection to Claims (Non-Adestros Gatheway)

Palazzo. Rapheal J. 90 Donovan Cornectional Fac Fac 1-5-225-4 POBOX 799001 San Diego CA 92179-9001

FILED
2005 JUN 10 PM 1: 55
US BANKRUPTCY COURT
DISTRICT OF DELAWARE

Basis for the amount of the claim is on come, past, present, future monitoring for Mesothilomia

Claim Number: 21

The claimant Rapleal J. Palazzo tas been exposed to Astestos in the form of W.R. Graces & Co. products while working in various construction applications such as.

Shipyard, Romoval and remstallation ashostos to ased attic insulation from 1972 to 1992. This prolonged exsposure to astostos, and to lated products by U.R. Grace and Co and its 61 entities makes the claimants health and safety and electricist and this it makes cause for future monitoring at the chimants expense.

Datod May 29,2005

Raphael & Pologgo



COST

Technical Services Provided by:

R. J. DONOVAN CORRECTIONAL FACILITY 480 Alta Road San Diego, CA 92179

PATIENT NAME:

PALAZZO, RALPH

DOB:

/1728-50` T_99035

ID#: REFERRED BY:

HUN

EXAM DATE:

5-13-05

71020 PA AND LATERAL CHEST

HISTORY: Asbestos exposure in shipyard. Need mesothelioma check.

COMPARISON: 7-21-05.

FINDINGS: Heart size is normal. No evidence of acute heart failure or pleural effusions. Mild degenerative spurs involves the lower thoracic spine anterioriy. No calcified pleural plaques are identified.

The lungs remain clear.

IMPRESSION: No evidence of acute cardiopulmonary disease.

William Snyder, M.D./jh~ D&T: 5-16-2005 DATE:

November 24, 2003

NAME:

PALAZZO, RALPH JAMES

CDC

NUMBER:

T-99035

APPEAL

NUMBER:

03-1113

SECOND LEVEL REVIEW

APPEAL DECISION:

PARTIALLY GRANTED

APPEAL ISSUE: You state that you are in need of special medical care for a condition that may develop into lung cancer due to years of working with asbestos in the shipvard. You also express concern regarding your Enhanced Outpatient Program (EOP) status. Specifically, you are requesting a transfer to the California Men's Colony (CMC) to ensure medical care.

APPEAL RESPONSE: In reaching a decision on this issue, a thorough review of your appeal has been conducted. The attached supporting documents, applicable sections of the California Code of Regulations (CCR) Title 15, and your Central File have been reviewed. In addition, on November 19, 2003, you were interviewed by R. Velo, Correctional Counselor II (CCII), and he discussed with you your concerns.


During the course of your interview with CCII Velo, you informed him of your work history, having direct contact with asbestos while employed in the shipyard industry. You stated that a medical doctor at the Richard J. Donovan Correctional Facility (RJDCF) recommended that you monitor your health conditions because asbestos is known to cause lung cancer. You informed CCII Velo of your desire to participate in a mental health program due to your EOP status. You also told him that you would like to transfer to CMC-East. CCII Velo informed you that during the week of November 24, 2003, would be interviewing you to complete your Reception Center processing, endorsement, and subsequent transfer. You stated you are doing fine at the RJDCF and

Based on the above information, your appeal is Partially Granted at the Second Level Review.

D. M. BARNES

Chief Deputy Warden (A)

···	<u>i</u>	·	<u> </u>	· • • • • • • • • • • • • • • • • • • •	
		LABORAT	ORY REPOR	1	
	FOUNDATION LABORATORY 620 S. Glendora Ave. Glendora, CA 91740 (628) 914-383B • Fax (628) 963-4471 M.Y. NASIR, M.D., LAB DIRECTOR ALLEN JAY M.D., LAB DIRECTOR	D		TO ALTA PI	N GORRECTIONAL FACTOR
BAGE 8:	30		The Contract of the Contract o	Myle I	FINAL
	TEST -1 5 225U	ABNORMAL	RESULT	UNITS	REFERENCE RANGE
	COPY TO DR. LYLE	100 100 100 100 100 100 100 100 100 100	À		_
HCV RNA	AR TYPING OT (bdna) THE LINEARITY OF THE LINEARITY OF THE COPIES/ML) AND 7,64 RESULTS OF LESS THE LEVEL OF DETECTION OF THE LEVEL OF DETECTION OF THE LEVEL OF TH	00,000 EU/NI NN 615 EU/NI PION FOR ENI	BETWEEN 6: (40,000,00 INDICATE) S ASSAY.	00 HCV RNA HCV VIRAL THIS ASSAN	A COPIES/ML) ASSAY IS BELOW IS INTENDED FOR
	THIS TEST WAS DEVE	OPED AND TE	PERFORMA	VCE CHARAC	TERISTICS
	DETERMINED BY QUEST CLEARED OR APPROVED CLEARANCE OR APPROVED REFER TO THE ANALY	TAL TO MOTE N	ECESSARY, I	DA HAS DET PERFORMANC HE TEST.	TERMINED THAT SUCH TE CHARACTERISTICS
	(NI) TEST PERFORMED		TITUTE 336	OS ORTEGA	HWY, SANJUANCAPISTRANO
	*				
	· - -				•
Signatu	ire:				
					or Marke



LABORATORY REPORT



FOUNDATION LABORATORY
620 S. Giendora Ave.
Glendora, CA 91740
(626) 914-3838 • Fax (626) 963-4470
M.Y. NASIR, M.D., LAB DIRECTOR
ALLEN JAY M.D., LAB DIRECTOR









r. Final •

### 1.85	TEST	ABNORMAL	RESULT	UNITS	REFERENCE RANGE
AGRATIO 1.5 Ratio 0.9-1.9 SGOT (AST) 1.0-6.2 SGOT (AST) 1.0-6.2 SGOT (AST) 1.0-6.0 SID-1.10	GLOBULIN		2.9		
SGOT (AST) SOPT (ALT) LD_SERUM LD_SERUM SOPT (ACTD, SERUM SOPT (AC	A/G RATIO	1.20	1.5		
SGPT (ALT)		, ST : 0 H : 52	•	· U/L	
154.00 91.180 154.00 91.180 16.30 16.30 16.70 26.70.2 26.7			46.00	υ/L	10-60
UNIC ACTD, SERUM ALK, PHOSPHATASE TOTAL BILIRUBIN 42.00 42.00 42.128 ADULT ADULT GGT, SERUM 42.00 40.00		N. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.		- •	91-180
### ADDIT	ED, DEKON IDTO ACTO CEDIM		6 30	mar/dL	2.6-7.2
### 10.70 mg/dL 0.1-1.5 Adult ### 2.00 U/L 7-64 ### 3.00 Adult ### 3.00 Adu	ALK DIOGDINANGE	12,11		1171.	
ADULT GGT, SERUM 42.00 U/L 7-64 ANEMIA PANEL FERRITIN 56.6 ng/mL 22-322 THYROID STUDIES TSH-3 4.05 UIU/mL 0.35-5.50 COAGULATION PT PATIENT 13.9 sec 10.0-14.0 PT RATIO 1.12 Ratio 1.0-1.4 PT RATIO 1.12 Ratio 1.0-1.4 1.12 Ratio 1.0-1.4 INDICATION ACCP (AMERICAN COLLEGE OF CHEST PHYSICIANS) ANTICOAGULANT THERAPY INDICATION PROPHYLAXIS OF VENOUS THROMBOSIS (HIGH-RISK SURGERY) TREATMENT OF VENOUS THROMBOSIS TREATMENT OF VENOUS THROMBOSIS TREATMENT OF VENOUS THROMBOSIS TREATMENT OF FUNCINGARY TORGILISM PREVENTION OF SYSTEMIC EMBOLISM: TISSUE HEART VALVES MYOCARDIAL INFRACTION ATRIAL FIBRILIATION ATRIAL FIBRILIATION MECHANICAL PROSTATIC VANVES PTT PATIENT PTT CONTROL Signature: Signature:		the second second second			
### ### ##############################	TOTAL BILIKOSIN	1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	. 0.70	mg/ cm	
ANEMIA PANEL FERRITIN 56.6 ng/mL 22-322 THYROID STUDIES TSH-3 4.05 UIU/mL 0.35-5.50 COAGULATION PT PATIENT 13.9 Sec 10.0-14.0 PT RATIO 1.12 Ratio 1.0-1.4 ISI VALUE PATIENT INR ACCP (AMERICAN COLLEGE OF CREST PHYSICIANS) ANTICOAGULANT THERAPY INDICATION FROPHYLAXIS OF VENOUS THROMBOSIS (HIGH-RISK SURGERY) TREATMENT OF VENOUS THROMBOSIS 2.0-3.0 MYOCAPOLAL INFARCTION ATRIAL FIBRILLATION MYOCAPOLAL INFARCTION ATRIAL FIBRILLATION MECHANICAL PROSTATIC VANVES 2.5-3.5 PTT PATIENT PTT CONTROL Signature: Signature:	·	1 11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		TT /T	7-61
ANEMIA PANEL FERRITIN 56.6 ng/mL 22-322 THYROID STUDIES THYROID STUDIES TSH-3 4.05 UIU/mL 0.35-5.50 COAGULATION PT PATIENT PT CONTROL PT RATIO 12.4 sec 10.0-14.0 PT RATIO 1.12 Ratio 1.0-1.4 INR ACCP (AMERICAN COLLEGE OF CREST PHYSICIANS) ANTICOAGULANT THERAPT INDICATION PROPHYLAXIS OF VENOUS THROMBOSIS (HIGH-RISK SURGERY) TREATMENT OF VENOUS THROMBOSIS (RIGH-RISK SURGERY) TREATMENT OF FULLMONARY PHOCILSM PREVENTION OF SYSTEMIC EMBOLISM: TISSUE HEART VALVES MYOCARDIAL INFARCTION ATRIAL FIBRILLATION ATRIAL FIBRILLATIO	GGT, SERUM		42.00	u/п	7-04
### THYROID STUDIES THYROID STUDIES TSH-3 #### 4.05 ###################################	ANEMIA PANEL		•		• .
TSH-3 COAGULATION PT PATIENT PT PATIENT 13.9 Sec 10.0-14.0 PT CONTROL PT CONTROL PT RATIO 11.12 Ratio 1.0-1.4 ISI VALUE PATIENT INR ACCP (AMERICAN COLLEGE OF CHEST PHYSICIANS) ANTICOAGULANT THERAPY INDICATION PROPHIAXIS OF VENOUS THROMBOSIS (HIGH-RISK SURGERY) TREATMENT OF VENOUS THROMBOSIS TREATMENT OF PULMONARY TEMECHISM PREVENTION OF SYSTEMIC EMBOLISM: TISSUE HEART VALVES ATRIAL FIBRILLATION MECHANICAL PROSTATIC VALVES PTT PATIENT PTT CONTROL Signature: Signature:	FERRITIN	100 Carlo 1660		ng/mL	. 22-322 .
TSH-3 COAGULATION PT PATIENT PT PATIENT 13.9 Sec 10.0-14.0 PT CONTROL PT CONTROL PT RATIO 11.12 Ratio 1.0-1.4 ISI VALUE PATIENT INR ACCP (AMERICAN COLLEGE OF CHEST PHYSICIANS) ANTICOAGULANT THERAPY INDICATION PROPHIAXIS OF VENOUS THROMBOSIS (HIGH-RISK SURGERY) TREATMENT OF VENOUS THROMBOSIS TREATMENT OF PULMONARY TEMECHISM PREVENTION OF SYSTEMIC EMBOLISM: TISSUE HEART VALVES ATRIAL FIBRILLATION MECHANICAL PROSTATIC VALVES PTT PATIENT PTT CONTROL Signature: Signature:	TUVEATA STIMIES	24.2	.		
13.9 Sec	TSH-3			'uIU/mL	0.35-5-50
### PATIENT 13.9 sec 10.0-14.0 PT CONTROL 12.4 sec 10.0-14.0 IST VALUE 1.9 Ratio ACCP (AMERICAN COLLEGE OF CHEST PHYSICIANS) ANTICOAGULANT THERAPY INDICATION FROPHYLAXIS OF VENOUS THROMBOSIS 2.0-3.0 (HIGH-RISK SURGERY) TREATMENT OF VENOUS THROMBOSIS 2.0-3.0 PREVENTION OF SYSTEMIC EMBOLISM 2.0-3.0 PREVENTION OF SYSTEMIC EMBOLISM 2.0-3.0 MYOCARDIAL INFARCTION 2.0-3.0 ATRIAL FIBRILLATION 2.0-3.0 ATRIAL FIBRILLATION 2.0-3.0 MECHANICAL PROSTATIC VAILUES 2.0-3.0 MECHANICAL PROSTATIC VAILUES 2.0-3.0 EXAMPLE OF THE PATIENT 2.0-3.0 ATRIAL FIBRILLATION 2.0-3.0 MECHANICAL PROSTATIC VAILUES 2.0-3.0 MECHANICAL PROSTATIC VAILUES 2.0-3.0 ATRIAL FIBRILLATION 2.0-3.0 MECHANICAL PROSTATIC VAILUES 2.0-3.0 ATRIAL FIBRILLATION 2.0-3.0 MECHANICAL PROSTATIC VAILUES 2.0-3.0 MECHANICAL PROSTATIC VAILUES 2.0-3.0 ATRIAL FIBRILLATION 2.0-3.0 MECHANICAL PROSTATIC VAILUES 2.0-3.0 MECHANI	GOD GETT BUTCHT	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	<i>;</i> •	· · .	• •
PT CONTROL PT RATIO 1.12 Ratio 1.0-1.4 ISI VALUE PATIENT INR ACCP (AMERICAN COLLEGE OF CHEST PHYSICIANS) ANTICOAGULANT THERAPY INDICATION PROPHYLAXIS OF VENOUS THROMBOSIS (HIGH-RISK SURGERY) TREATMENT OF VENOUS THROMBOSIS PREVENTION OF SYSTEMIC EMBOLISM PREVENTION OF SYSTEMIC EMBOLISM TISSUE HEART VALVES ATRIAL FIBRILLATION ATRIAL FIBRILLATION MECHANICAL PROSTATIC VALVES PTT PATIENT PTT CONTROL Signature: Signature:				and	10 0-14 0
PT RATIO ISI VALUE PATIENT INR ACCP (AMERICAN COLLEGE OF CHEST PHYSICIANS) THERAPEUTIC RANGE FOR ORAL ANTICOAGULANT THERAPY INDICATION PROPHYLAXIS OF VENOUS THROMBOSIS (HIGH-RISK SURGERY) TREATMENT OF VENOUS THROMBOSIS PREVENTION OF SYSTEMIC EMBOLISM PREVENTION OF SYSTEMIC EMBOLISM: TISSUE HEART VALVES MYOCARDIAL INFARCTION ATRIAL FIBRILLATION MECHANICAL PROSTATIC VALVES PTT PATIENT PTT CONTROL Signature: Signature:					
ISI VALUE PATIENT INR ACCP (AMERICAN COLLEGE OF CHEST PHYSICIANS) THERAPEUTIC RANGE FOR ORAL ANTICOAGULANT THERAPY INDICATION PROPHYLAXIS OF VENOUS THROMBOSIS (HIGH-RISK SURGERY) TREATMENT OF VENOUS THROMBOSIS PREVENTION OF SYSTEMIC EMBOLISM TISSUE HEART VALVES MYOCARDIAL INFARCTION ATRIAL FIBRILLATION MECHANICAL PROSTATIC VALVES PTT PATIENT PTT CONTROL Signature: Signature: 1.9 1.2 Ratio RANGE FOR ORAL 2.0-3.0 2.0-3.0 2.0-3.0 2.0-3.0 2.0-3.0 2.0-3.0 2.0-3.0 30.7 Sec 25-36.3 27.8-32.0					
PATIENT INR ACCP (AMERICAN COLLEGE OF CREST PHYSICIANS) ANTICOAGULANT THERAPT INDICATION PROPHYLAXIS OF VENOUS THROMBOSIS (HIGH-RISK SURGERY) TREATMENT OF VENOUS THROMBOSIS TREATMENT OF PULMONARY EMBOLISM PREVENTION OF SYSTEMIC EMBOLISM: TISSUE HEART VALVES MYOCARDIAL INFARCTEON ATRIAL FIBRILLATION MECHANICAL PROSTATIC VALVES PTT PATIENT PTT CONTROL Signature: Signature: 1.2 Ratio THRAPEUTIC RANGE FOR ORAL INR 2.0-3.0 2.0-3.0 2.0-3.0 2.0-3.0 2.0-3.0 2.5-3.5 SEC 25-36.3 27.8-32.0				Katio	1.0-1.4
PATIENT INR ACCP (AMERICAN COLLEGE OF CHEST PHYSICIANS) THERAPEUTIC RANGE FOR ORAL ANTICOAGULANT THERAPY INDICATION PROPHYLAXIS OF VENOUS THROMBOSIS (HIGH-RISK SURGERY) TREATMENT OF VENOUS THROMBOSIS TREATMENT OF PULMONARY EMBOLISM PREVENTION OF SYSTEMIC EMBOLISM: TISSUE HEART VALVES TISSUE HEART VALVES AVOCARDIAL INFARCTEON ATRIAL FIBRILLATION MECHANICAL PROSTATIC VALVES PTT PATIENT 10.00 ACCP (AMERICAN COLLEGE OF CHEST PHYSICIANS) TINR ANTICOAGULANT THROMBOSIS 2.0-3.0 2.0-3.0 2.0-3.0 2.0-3.0 2.0-3.0 2.0-3.0 3.0 3.0-3.0 3.0 3.0-3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0		1 1 1 1 N 1 1 N 1 1 1 1			
ANTICAGULANT THERAPY INDICATION PROPHYLAXIS OF VENOUS THROMBOSIS (HIGH-RISK SURGERY) TREATMENT OF VENOUS THROMBOSIS TREATMENT OF PULMONARY EMBOLISM PREVENTION OF SYSTEMIC EMBOLISM: TISSUE HEART VALVES MYOCARDIAL INFARCTION ATRIAL FIBRILLATION MECHANICAL PROSTATIC VAIVES PTT PATIENT 10.7 2.0-3.0 2.0-3.0 2.0-3.0 2.0-3.0 2.0-3.0 2.0-3.0 2.0-3.0 30.7 2.0-3.0 2.0-3.0 2.0-3.0 2.0-3.0 2.0-3.0 2.0-3.0 2.0-3.0 30.7 2.0-3.0 2.0-	PATIENT INR		1.2	Ratio	
ANTICAGULANT THERAPY INDICATION PROPHYLAXIS OF VENOUS THROMBOSIS (HIGH-RISK SURGERY) TREATMENT OF VENOUS THROMBOSIS TREATMENT OF PULMONARY EMBOLISM PREVENTION OF SYSTEMIC EMBOLISM: TISSUE HEART VALVES MYOCARDIAL INFARCTION ATRIAL FIBRILLATION MECHANICAL PROSTATIC VAIVES PTT PATIENT 10.7 2.0-3.0 2.0-3.0 2.0-3.0 2.0-3.0 2.0-3.0 2.0-3.0 2.0-3.0 30.7 2.0-3.0 2.0-3.0 2.0-3.0 2.0-3.0 2.0-3.0 2.0-3.0 2.0-3.0 30.7 2.0-3.0 2.0-	ACCP (AMERICAN COI	LEGE OF CHE	ST PHYSICIAN	S) THERAPEUI	IC RANGE FOR ORAL
(HIGH-RISK SURGERY) TREATMENT OF VENOUS THROMBOSIS TREATMENT OF PULMONARY EMBOLISM PREVENTION OF SYSTEMIC EMBOLISM: TISSUE HEART VALVES MYOCARDIAL INFARCTION ATRIAL FIBRILLATION MECHANICAL PROSTATIC VALVES PTT PATIENT PTT CONTROL Signature: Signature:	ANTICOAGULANT THE	RAPY	.		•
(HIGH-RISK SURGERY) TREATMENT OF VENOUS THROMBOSIS TREATMENT OF PULMONARY EMBOLISM PREVENTION OF SYSTEMIC EMBOLISM: TISSUE HEART VALVES MYOCARDIAL INFARCTION ATRIAL FIBRILLATION MECHANICAL PROSTATIC VALVES PTT PATIENT PTT CONTROL Signature: Signature:	TNDICATION	7.1	i '	INR	•
(HIGH-RISK SURGERY) TREATMENT OF VENOUS THROMBOSIS TREATMENT OF PULMONARY EMBOLISM PREVENTION OF SYSTEMIC EMBOLISM: TISSUE HEART VALVES MYOCARDIAL INFARCTION ATRIAL FIBRILLATION MECHANICAL PROSTATIC VALVES PTT PATIENT PTT CONTROL Signature: Signature:	PROPHYLAXIS OF VE	INOUS THROMB	OSIS	2.0-3.0	,
TREATMENT OF PULMONARY EMBOLISM PREVENTION OF SYSTEMIC EMBOLISM: TISSUE HEART VALVES MYOCARDIAL INFARCTION ATRIAL FIBRILLATION MECHANICAL PROSTATIC VALVES PTT PATIENT PTT CONTROL Signature: Signature:	' (HTGH-RISK SURGER	(Υ)			
TREATMENT OF PULMONARY EMBOLISM PREVENTION OF SYSTEMIC EMBOLISM: TISSUE HEART VALVES MYOCARDIAL INFARCTION ATRIAL FIBRILLATION MECHANICAL PROSTATIC VALVES PTT PATIENT PTT CONTROL Signature: Signature:	TORATMENT OF VENC	MA CHTE S TI	TS .	2.0-3.0	
PREVENTION OF SYSTEMIC EMBOLISM: TISSUE HEART VALVES MYOCARDIAL INFARCTION ATRIAL FIBRILLATION MECHANICAL PROSTATIC VALVES PTT PATIENT PTT CONTROL Signature: Signature:		CONTROL DIVIDION	TSM	2.0-3.0	•
TISSUE HEART VALVES MYOCARDIAL INFARCTION ATRIAL FIBRILLATION MECHANICAL PROSTATIC VALVES PTT PATIENT PTT CONTROL Signature: Signature:	POSITION OF CAST		TGM.	. =	
MYOCARDIAL INFARCTION ATRIAL FIBRILLATION MECHANICAL PROSTATIC VALVES PTT PATIENT PTT CONTROL Signature: Signature:	NEATHER ALPHA	TENTE BUDON	,	2 ብ-3 በ	•
ATRIAL FIBRILLATION MECHANICAL PROSTATIC: VALVES PTT PATIENT PTT CONTROL Signature: Signature:	TISSUE HEART VAL	THE COT	•		
MECHANICAL PROSTATIC VAIVES 2.5-3.5 PTT PATIENT Sec 25-36.3 PTT CONTROL 30.7 sec 27.8-32.0 Signature:	MYOCARDIAL INFARC	THOM:	-	2.0-3.0	
PTT PATIENT 25-36.3 PTT CONTROL 30.7 sec 27.8-32.0 Signature:	ATRIAL FIBRILLAT	LUN	•		
PTT PATIENT 25-36.3 PTT CONTROL 30.7 sec 27.8-32.0 Signature:		TIC:VALVES	•		ባር ኃይ ን
Signature:	PTT PATIENT	41.8 H:			
Signature:	PTT CONTROL		- 30.7	sec	27.8-32.0
	• •		•		
	l		-		•
	Signature:				
		+;	<u>-</u>		
			- •	.u. 10	· b .
	·		,		

LABORATORY REPORT



FOUNDATION LABORATORY
1716 West Holl Ave,
Pomona, CA 91768
(909) 623-9301 • Fax (909) 623-9306
M.Y. NASIR, M.D., LAB DIRECTOR
ALLEN JAY M.D., LAB DIRECTOR











HEMATOLOGY WBC RBC 5.50 106/uL 4.5-11.0 RBC 5.50 106/uL 4.6-6.2 HCT 48.7 42-52 MCV 88.5 MCH 30.1 PS 27-34 MCHC 31.5-36.0 6.8-10.6 REPW 9.7 CU/mma 6.8-10.6 REPW 9.7 CU	TEST F1 5 225	ABNORMAL	RESULT	UNITS	REFERENCE RANGE
REC					
S.50		2 P 2 P 2 P 2 P 2 P 2 P 2 P 2 P 2 P 2 P	•	•	
16.6 g/dL 14-18				- 103/uL	4.5-11.0
High 16.6 g/dL 14-18 48.7 \$ 42-52 42-52 42-62 48.7 42-52 42-62 48.7 42-52 48.7 42-52 48.7 4			5.50	106/uL	4.6-6.2
HCT	HgB '	'	16.6	q/dL	
## ACH	łČT	''''	48.7	٠	42-52
## ACH ## ACC ##			88.5	um3	80-94
MACHC 34.0	ICH				
### 11-14.8 #### 103/uL 150-400 ##################################	MCHC			\$	31.5-36.0
PLATELETS #PV 9.7 cu/mm 6.8-10.6 #PANULOCYTES \$ 60.1 \$ 48.9-69.9 #RANULOCYTES \$ 28.8 \$ 22.4-43.6 #PHHOCYTES \$ 28.8 \$ 22.4-43.6 #PHHOCYTES \$ 1.79 103/uL 1.5-4.0 #MONOCYTES \$ 1.045 103/uL 1.5-4.0 #MONOCYTES \$ 1.045 103/uL 0.2-0.8 #MONOCYTES \$ 0.45 103/uL 0.2-0.8 #MONOCYTES \$ 0.05 103/uL 0.2-0.8 #MONOCYT	RDW	-16.2 li -			
## 9.7 Cu/mm 6.8-10.6 ## 8RANULOCYTES			23`5		
### 60.1	/PV	<u> </u>			
### 3.74 103/uL 1.5-6.7 LYMPHOCYTES		<u> </u>	60.1		
28.8				_	
1.79 103/uL 1.5-4.0					
MONOCYTES \$ 7.2 \$ 6.2-9.8 MONOCYTES # 0.45 103/uL 0.2-0.8 EOSINOPHIL \$ 3.2 \$ 0-5.0 EOSINOPHIL # 0.20 103/uL 0-0.40 EOSINOPHIL # 0.04 103/uL 0-0.40 EOSINOPHIL # 0.04 103/uL 0-0.20 EOSINOPHIL # 0.20 EOS	LYMPHOCYTES#				
MONOCYTES# 0.45 103/uL 0.2-0.8	MONOCYTES &				
3.2			• •		
0.20 103/uL 0-0.40		. 1			
COAGULATION PATIENT 12.2 Sec 10.0-14.0 PATIENT 12.0 Sec 10.0-14.0 PATIENT INR 1.0 Ratio ACCP(AMERICAN COLLEGE OF CHEST PHYSICIANS) THERAPEUTIC RANGE FOR OR ANTICOAGULANT THERAPY, INDICATION INR PROPHYLAXIS OF VENOUS THROMBOSIS 2.0-3.0 (HIGH-RISK SURGERY)		<u> </u>			
O.04 103/UL 0-0.20 RBC MORPHOLOGY NOrmal IMMUNOLOGY NEGATIVE NEGATIVE COAGULATION PT PATIENT 12.2 sec 10.0-14.0 PT CONTROL 12.0 sec 10.0-14.0 ISI VALUE 1.99 PATIENT INR 1.0 Ratio ACCP (AMERICAN COLLEGE OF CHEST PHYSICIANS) THERAPEUTIC RANGE FOR OR ANTICOAGULANT THERAPY. INDICATION INR PROPHYLAXIS OF VENOUS THROMBOSIS 2.0-3.0 (HIGH-RISK SURGERY)	· · · · · · - · · · · · · ·	<u> </u>			
REC MORPHOLOGY IMMUNOLOGY HAV A AB TOTAL COAGULATION PT PATIENT PT CONTROL ISI VALUE PATIENT INR ACCP (AMERICAN COLLEGE OF CHEST PHYSICIANS) INDICATION PROPHYLAXIS OF VENOUS THROMBOSIS (HIGH-RISK SURGERY) NOTMAL NEGATIVE 10.0-14.0 10.0-14.0 11.99 PATIENT INR ACCP (AMERICAN COLLEGE OF CHEST PHYSICIANS) THERAPEUTIC RANGE FOR OR ANTICOAGULANT THERAPY. INDICATION INR PROPHYLAXIS OF VENOUS THROMBOSIS 2.0-3.0					
IMMUNOLOGY HAV A AB TOTAL PERMITTION PT PATIENT CONTROL ESI VALUE PATIENT INR ACCP (AMERICAN COLLEGE OF CHEST PHYSICIANS) ANTICOAGULANT THERAPY. INDICATION PROPHYLAXIS OF VENOUS THROMBOSIS (HIGH-RISK SURGERY) INEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE 12.2 sec 10.0-14.0 10.0-14.0 Ratio Ratio INR INR INR PROPHYLAXIS OF VENOUS THROMBOSIS 2.0-3.0				402700	0 0.20
IMMUNOLOGY HAV A AB TOTAL COAGULATION PT PATIENT PT CONTROL ISI VALUE PATIENT INR ACCP (AMERICAN COLLEGE OF CHEST PHYSICIANS) THERAPEUTIC RANGE FOR OR ANTICOAGULANT THERAPY. INDICATION PROPHYLAXIS OF VENOUS THROMBOSIS (HIGH-RISK SURGERY) NEGATIVE 10.0-14.0 10.0-1			TOT IIM		
HAV A AB TOTAL COAGULATION PT PATIENT PT CONTROL ISI VALUE PATIENT INR ACCP (AMERICAN COLLEGE OF CHEST PHYSICIANS) ANTICOAGULANT THERAPY. INDICATION PROPHYLAXIS OF VENOUS THROMBOSIS (HIGH-RISK SURGERY) NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE 10.0-14.0 10.0-14.0 10.0-14.0 Ratio Ratio INR 1.0 ANTICOAGULANT THERAPY. INDICATION INR PROPHYLAXIS OF VENOUS THROMBOSIS 2.0-3.0	TMMTINOT.OGY .				•
COAGULATION PT PATIENT 12.2 sec 10.0-14.0 PT CONTROL 12.0 sec 10.0-14.0 1.99 PATIENT INR 1.0 Ratio ACCP (AMERICAN COLLEGE OF CHEST PHYSICIANS) THERAPEUTIC RANGE FOR OR ANTICOAGULANT THERAPY. INDICATION PROPHYLAXIS OF VENOUS THROMBOSIS (HIGH-RISK SURGERY) 12.2 sec 10.0-14.0 Rec 10.0-14.0 INR 10.0-14.0 10.0-14.0 INR 10.0-14.0 INR 2.0-3.0		<u> </u>	NECATIVE		NEC PATTE
PT PATIENT 12.2 SeC 10.0-14.0 PT CONTROL 12.0 SeC 10.0-14.0 ISI VALUE 1.99 PATIENT INR 1.0 Ratio ACCP (AMERICAN COLLEGE OF CHEST PHYSICIANS) THERAPEUTIC RANGE FOR OR ANTICOAGULANT THERAPY. INDICATION INR PROPHYLAXIS OF VENOUS THROMBOSIS 2.0-3.0 (HIGH-RISK SURGERY)	mv n mb tornu		· · · · · · · · · · · · · · · · · · ·		NDWALLVD
PT PATIENT 12.2 SeC 10.0-14.0 PT CONTROL 12.0 SeC 10.0-14.0 ISI VALUE 1.99 PATIENT INR 1.0 Ratio ACCP (AMERICAN COLLEGE OF CHEST PHYSICIANS) THERAPEUTIC RANGE FOR OR ANTICOAGULANT THERAPY. INDICATION INR PROPHYLAXIS OF VENOUS THROMBOSIS 2.0-3.0 (HIGH-RISK SURGERY)	COAGULATION	·			
PT CONTROL 12.0 sec 10.0-14.0 ISI VALUE 1.99 PATIENT INR 1.0 Ratio ACCP (AMERICAN COLLEGE OF CHEST PHYSICIANS) THERAPEUTIC RANGE FOR OR ANTICOAGULANT THERAPY. INDICATION INR PROPHYLAXIS OF VENOUS THROMBOSIS 2.0-3.0 (HIGH-RISK SURGERY)		<u> </u>	12.2	sec	10.0-14.0
ISI VALUE 1.99 PATIENT INR 1.0 Ratio ACCP(AMERICAN COLLEGE OF CHEST PHYSICIANS) THERAPEUTIC RANGE FOR OR ANTICOAGULANT THERAPY. INDICATION INR PROPHYLAXIS OF VENOUS THROMBOSIS 2.0-3.0 (HIGH-RISK SURGERY)					
PATIENT INR ACCP (AMERICAN COLLEGE OF CHEST PHYSICIANS) THERAPEUTIC RANGE FOR OR ANTICOAGULANT THERAPY. INDICATION PROPHYLAXIS OF VENOUS THROMBOSIS (HIGH-RISK SURGERY) 10 Ratio Ratio INR INR 2.0-3.0	IST VALUE	2			2010 2210
ACCP (AMERICAN COLLEGE OF CHEST PHYSICIANS) THERAPEUTIC RANGE FOR OR ANTICOAGULANT THERAPY. INDICATION PROPHYLAXIS OF VENOUS THROMBOSIS (HIGH-RISK SURGERY) INR 2.0-3.0				Ratio	
ANTICOAGULANT THERAPY. INDICATION INR PROPHYLAXIS OF VENOUS THROMBOSIS 2.0-3.0 (HIGH-RISK SURGERY)		LIECE OF CHES			IC RANGE FOR OPAL
INDICATION INR PROPHYLAXIS OF VENOUS THROMBOSIS 2.0-3.0 (HIGH-RISK SURGERY)					
PROPHYLAXIS OF VENOUS THROMBOSIS 2.0-3.0 (HIGH-RISK SURGERY)				TNR	•
(HIGH-RISK SURGERY)		ENOUS TUROMEO	QTQ .		
			سان پ	2.0 3.0	
TAMPINENT OF ADUCA S TEMPONDAS TO 7.0.3.0			a	5 A-2 B	
	THEMINENT OF ABIN	AA B		2.0-3.0	

1/4/1/15

<i>f</i>	. 0		·	•	
LABORATORY REPORT					
1716 West Holt Ave. Pomona, CA 91768 (809) 623-9301 • Fau M.Y. NASIR, M.D., LA	((909) 623-9306 AB DIRECTOR		ELI FUE DOMONAN 180 ALEA: RUI MOSPITAL/COM AN DIEGO CO	EORRECTIONS # RUID 30 LC: 92.1-29	70.
:12				MI GRIDY TO	L
TEST	ABNORMAL	RESULT	UNITS	REFERENCE R	ANGE
TREATMENT (PREVENTION TISSUE HEAD MYOCARDIAL ATRIAL FIBS	OF PULMONARY EMBO OF SYSTEMIC EMBO RT VALVES INFARCTION RILLATION	Lism	· 2.0-3.0 · 2.0-3.0 2.0-3.0 2.0-3.0)))	/ <u>;</u>
TIENT .	- 35:5 H.	<u>.</u> - 27.49	sec	25,0-3	4.0
,					
ıre:					
	1716 West Holt Ave. Pomone, CA 91768 (809) 523-9301 • Fa. M.Y. NASIR, M.D., L.A ALLEN JAY M.D., LA TEST TREATMENT PREVENTION TISSUE HEAI MYOCARDIAL ATRIAL FIBH MECHANICAL FIENT NTROL	TEST ABNORMAL TRIBATMENT OF PULMONARY EMBO PREVENTION OF SYSTEMIC EMBO ATRIAL FIBRILLATION MECHANICAL PROSTATIC VALVES TIENT TYROL ATRIAL AT	FOUNDATION LABORATORY 1716 West Holl Ave. Primane, CA 91788 (809) 623-9306 (M.Y. NASIR, M.D., LAB DIRECTOR ALLEN JAY M.D., LAB DIRECTOR ALLEN JAY M.D., LAB DIRECTOR ALLEN JAY M.D., LAB DIRECTOR TEST ABNORMAL RESULT TREATMENT OF PULMONARY EMBOLISM: TISSUE HEART VALVES MYOCARDIAL INFARCTION ATRIAL FIBRILLATION MECHANICAL PROSTATIC VALVES TIENT NTROL 27.49 27.49	TEST ABNORMAL RESULT UNITS TRIATMENT OF PULMARARY EMBORISM: TISSUE HEART VALVES EMBORISM: ATRIAL FIBRILLATION MECHANICAL PROSTATIC VALVES TIENT TYPOL 2.0-3.0 2.5-3.5 TRING MECHANICAL PROSTATIC VALVES TRING MECHANICAL PROSTATIC VALVES TRING MECHANICAL PROSTATIC VALVES TRING MECHANICAL PROSTATIC VALVES 2.5-3.5 SEC STEMIC SEC SEC SEC SEC SEC SEC SEC SEC SEC SE	LABORATORY REPORT FOUNDATION LABORATORY 1716 Was Hold Ave. Penners, Ca 97768 (2009 623-9306 RAY, NASIR, MD, LAB DIRECTOR) ALEN JAY MD, LAB DIRECTOR ALEN JAY MD, LAB DIRECTOR ALEN JAY MD, LAB DIRECTOR AND TRANSPORT OF PULMONARY PROBULES. TISSUE HEART VALVES TISSUE HEART VALVES ANYOCARDIAL INFACTION ARYCLADIAL INFACTION ARYCLADIAL INFACTION ARYCLADIAL INFACTION ARYCLADIAL INFACTION 2.0-3.0 ARKHAIN FIBRILLATION 2.0-3.0 ARKHAIN FIBRILLATION 2.0-3.0 BECHANICAL PROSTATIC VALVES Sec 25.0-3. Sec 25.0-3. Sec 24.8-21

) YAT	e of California-Health and Welfare :	NGENCY	DEPARTMENT OF MENTAL HEALTH		
	GUIDELINES	DATE OF REPORT: 8 240 4 DATE DICTATED:			
1-	IDENTIFICATION DATA	E3 11.0. care of from	PJD CTF to Az on		
2.	PRIOR HISTORY: (Include, previous psychiatric hospitalizations, treatment and significant past psychiatric and medical history	Hospoy for further programmed Sunner Cymptoms prod Depression, (mood Sunn Dattimpt. HD45lexia	(95) Described though		
3.	CHIEF COMPLAINT/REASON FOR ADMISSION: (Include reasons identified by patient and/or other sources.)	-Parixiety, paranoia,	presserved speech,		
4.	PHYSICAL AND MENTAL STATUS AT ADMISSION:		(1) (1)		
5,	HOSPITAL COURSE: Canger to self-others; other psychiatric.	Pureral Problem: Hep & Joulune 1050 Eczema 6			
6.	HOSPITAL COURSE: Physical problems	Heitany: Departate Temenin Hospital Course = Patiego			
7.	MENTAL STATUS AT RELEASE	the will - let ferst be d	auraliantion (patterit		
8.	Current Legal Status and Reason for Release:	the He were noted in	the some sarcastic		
9.	DSM DIAGNOSIS: (At five axis)	behavior above serving	AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA		
10.	RECOMMENDATIONS FOR PHYSICAL & PSYCHIATRIC FOLLOW-UP: a. Medications/dist/activity limitations b. Other, e.g., Hepalitis follow-up, locked or unlocked setting.	control. Repréd is b il. Sleip agnéd is b Der Bourne, M. D. So f inexpectated by it He has neached maxin program. Magnésis-I Bioches-Desend	the is generally polit		
- N	C-DAGCUTA-	M.D. CADROLLITO WO SIGNATURE(Back of form must be signed a	M.D. 8/04/04. DATE Therearceration		
	17-55 DIMY	epaprica, DID, Hep C(+) Ecz Discharge to RID, curr	ent medication Mapricay		
CONFIDENTIAL PATIENT REPORTATION I JUdy need CHAP Machine. SEE W & 1 CODE SECTION SIZE RENding Deagnases Confirmation of					
	1 5741A (Mensed 1/56) DISTURDADALLE	EGE SIMMARY	GORE RECORD		
8.00	the commu	reathing pupiler (per I mity hospital - ie Eleup	Der Baurraph D.) from		

•	
ME and NUMBER	CDC-128-€
•	CDC NUMBER: T99035 CDC 128-C
PALAZZO, RALPH	R.J. Donovan Correctional Facility F1050000000225U
	ANNUAL TB CHRONO
DISTRIBUTION	TB SKIN TESTING
GENTRAL FILE: MEDICAL FILE: INMATE: IX	INMATE TB ALERT CODE 33-
	Carry lyle Do
TE 05-04-2005	LN, LYLE, D.O., M.S., DIRECTOR, PUBLIC HEALTH @ RIDGF MEDICAL—PSYCHIATRIC—DENTAL

Exhibit A

Test tesults of latest X-Ray from Physicians Madical Group (tabliology)

Exhibit B Modical Appeal No. 03-1113 State of California questing monitoring For Mosothi binia.

Exhibit C Laboratory Roport/Foundation Laboratory Accession Nos. 695731, 69573, 732557

Exhibit D Modical Discharge Summary/Dept. Merbal Health #534.0

Akhyal TB Chrono / TB Skin Tests State of California